Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION An FAERS cluster in a demographic the trials under-enrolled put 505(b)(2) literature-to-product bridge table in front of pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / CMC and Development Pathways decision is the 505(b)(2) bridge is from 505(b)(2) literature-to-product bridge table, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.